MedTrace Logo

Intravenous Esketamine on Prevention of Postoperative Depression in Patients Undergoing Cardiac Surgery

NCT05155969 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2021-12-14

No results posted yet for this study

Summary

Esketamine is a general anesthetic with anti-depressant effects at subanaesthetic doses. This study hypothesized that intraoperative administration of ketamine would prevent or mitigate postoperative depressive symptoms in surgical patients.

Conditions

  • Postoperative Depression

Interventions

DRUG

Esketamine

esketamine (0.3 mg/kg in 100 ml normal saline) is intravenously infused 40 minutes before anesthesia induction

DRUG

Normal saline

Normal saline will be administrated intravenously at the dural opening, with a total dose of 0.5 ml/kg and continual infusion for 40 minutes.

Sponsors & Collaborators

  • Anshi Wu

    lead OTHER

Principal Investigators

  • Anshi Wu Wu, Ph.D · Beijing Chao-Yang Hospital, Capital Medical Unive

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2021-12-05
Completion
2022-12-15

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05155969 on ClinicalTrials.gov